Archemix’ ARC1779 Granted Orphan Designation for the Treatment of TTP, a Life-Threatening Blood Disorder – Archemix Corp. announced that ARC1779 has received orphan drug designation from the U.S. Food and Drug Administration. ARC1779, a novel aptamer therapeutic, is a first-in-class anti-platelet agent for the treatment of a rare, life-threatening blood disorder known as thrombotic thrombocytopenic purpura, or TTP. There is no drug approved for the treatment of TTP and acute episodes of TTP are associated with a significant mortality rate, estimated to be as high as 20 percent. More

Archemix Announces Initiation of Phase 2 Trial for Aptamer Product Candidate ARC1779 in Patients with TTP, a Rare, Life-Threatening Blood Disorder – Archemix Corp. announced that it started a Phase 2 clinical trial of ARC1779, which is designed to evaluate the safety and efficacy of ARC1779 as a first-in-class anti-platelet agent in patients suffering from a rare, life-threatening blood disorder known as thrombotic thrombocytopenic purpura, or TTP. More

Archemix CEO to Present at the 28th Annual Cowen and Company Health Care Conference – Archemix Corp. announced today that Dr. Errol De Souza, Archemix’s President and Chief Executive Officer, will present at the 28th Annual Cowen and Company Health Care Conference in Boston on Monday, March 17th at 9:30 a.m. More

Archemix Earns Milestone Payment from Initiation of Phase 1 Clinical Trial by Ophthotech – Archemix Corp. received a milestone payment from its collaborator Ophthotech Corp. The milestone payment has been triggered by Ophthotech's enrollment of the first volunteer in a Phase 1 study of E10030, an anti-platelet derived growth factor (PDGF) aptamer which is being developed for age related macular degeneration (AMD). More

Archemix and NascaCell Expand Strategic Alliance for Aptamer-based Drug Discovery – Archemix Corp. and NascaCell Technologies AG announced today an expansion of their strategic alliance focused on the use and development of aptamers for drug discovery applications. More